IL1B and myocardial infarction: A total of 10,061 patients with a previous myocardial infarction and showing inflammatory residual risk (CRP > 2 mg/L) under optimal CV-protective therapy were enrolled in this randomized, double-blind trial to receive canakinumab, a IL-1β inhibitory monoclonal antibody, or a placebo every 3 months.